After a long hiatus, we are pleased to announce that we will begin posting opinions about FDA events again. We also would like to announce the addition of two new contributors to our site, Dan Heathwood and Tim Shields. Both are private investors with previous experience working as research analysts for some well known investment firms. Their past contributions outside of pdufadate.com have helped translate our opinions into sound stock trading advice. Our first post will probably deal with Durata Therapeutics (DRTX) as we continue to receive numerous emails about dalbavancin.
There will be lots of changes to our site so keep checking back.